Penile Cancer Clinical Trial Data: Sintilimab Combined with Chemotherapy

A Chinese clinical trial dataset from a prospective, non-randomized study evaluating sintilimab combined with chemotherapy for locally advanced penile squamous cell carcinoma. The dataset likely contains outcomes for 25 enrolled patients, including progression-free survival, objective response rate, and adverse events. The study is registered with the Chinese Clinical Trial Registry (ChiCTR2400094629) and was last updated in March 2026.

Use Cases

• Predict progression-free survival based on treatment modality (neoadjuvant-adjuvant vs adjuvant-only)
• Analyze the correlation between radiological response (CR/PR vs SD/PD) and patient outcomes
• Model the relationship between PD-L1 expression levels (CPS ≥20) and treatment efficacy
• Evaluate the safety profile of combined therapy based on adverse event rates

Strengths

• Data is from a registered, prospective clinical trial (ChiCTR2400094629), suggesting structured collection
• Preliminary analysis includes results for 25 patients with a median follow-up of 20 months
• Outcomes include multiple clinical metrics: ORR (52.9%), DCR (76.5%), pCR, MPR, PFS (71.4%), OS (90.0%)

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The dataset is very small (117.0 KB), indicating limited scope

Provenance

Source

figshare, author Shanshan Xu

Collection Method

Prospective, non-randomized, two-cohort clinical study

Time Range

Study period not specified; preliminary analysis based on 20-month median follow-up

Freshness

Last updated 2026-03-19 06:49:50

Geography

Likely China, based on registration with Chinese Clinical Trial Registry